Development, Reliability, and Validity of a New Preference and Satisfaction Questionnaire

Abstract

The PSQ is a valid and reliable measure and may be a valuable tool to assess patient preference and satisfaction with a weekly oral tablet and 6-month subcutaneous injection for postmenopausal bone loss.

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

“…At each visit, subjects completed an adaptation of the Beliefs about Medicines Questionnaire (BMQ) [21] that included 22 specific questions in the following three major domains: necessity of the prescribed medication for controlling osteoporosis now and in the future, concerns about the potential adverse effects of taking the prescribed medication for controlling osteoporosis, and preference for one medication over the other. At 6 and 12 months, subjects completed the Bother subscale (five-point scale ranging from "not at all bothered" to "severely bothered") and the Satisfaction subscale (five-point scale from "not at all satisfied" to "very satisfied"), which were taken from the Patient Satisfaction Questionnaire (PSQ) [22]. Subjects completed the BMQ and PSQ questions prior to any other study procedures.…”

Development and validation of an osteoporosis treatment questionnaire (OSTREQ) evaluating physicians’ criteria in the choice of treatment

“…[26][27][28] Furthermore, there are studies evaluating questionnaires based on patients' preferences regarding osteoporosis treatment. [29][30][31][32] However, all these tools are exclusively addressed to patients. In the present study, we aimed to develop what is, to the best of our knowledge, the first questionnaire evaluating the factors that influence the physician's decision to initiate, continue or change a regimen for osteoporosis treatment.…”

Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass

“…Development and validation of the PSQ is reported separately [29]. Briefly, the PSQ was developed from a pool of potential questions derived from a review of the published literature and input from topic experts.…”

“…The PSQ was administered to patients in 14 countries in 18 languages. The US English version of the PSQ was the most commonly completed (33%), followed by the Danish (11%) and Canadian English (11%) versions [29]. In all 14 countries, more patients preferred the injection over the tablet (Supplementary Table 1).…”

“…However, there have been no data that characterize patient preference and satisfaction with 6-month subcutaneous injections. The Preference and Satisfaction Questionnaire (PSQ) was developed specifically to evaluate patient preference and satisfaction with two different modes and frequency of dosing for the treatment of postmenopausal bone loss: a subcutaneous injection administered every 6 months (Q6M) and an oral tablet taken once weekly (QW) [29]. We report the results of patient responses to the PSQ from two blinded phase 3 head-to-head randomized controlled trials that directly compared denosumab with alendronate [30,31].…”